A Study to Assess the Safety, Tolerability, Pharmacokinetics & Efficacy of

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05945537` - A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH	Phase 1
Recruiting	`NCT05462353` - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH	Phase 2
Recruiting	`NCT05065593` - The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis	N/A
Terminated	`NCT04171765` - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis	Phase 2
Recruiting	`NCT04365855` - The Olmsted NAFLD Epidemiology Study (TONES)	N/A
Active, not recruiting	`NCT02912260` - Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)	Phase 2
Recruiting	`NCT06054815` - Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH	Phase 2
Completed	`NCT02784444` - A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH	Phase 2
Not yet recruiting	`NCT06160271` - Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis	Phase 2
Active, not recruiting	`NCT05573204` - Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients With Non-alcoholic Steatohepatitis	Phase 2
Completed	`NCT04042142` - Glucagon Resistance in Patients With NAFLD	N/A
Completed	`NCT04657523` - Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study	N/A
Completed	`NCT04142424` - A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects	Phase 1
Terminated	`NCT02787304` - Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)	Phase 2
Recruiting	`NCT04666402` - Integrated Diagnostics for Early Diagnosis of Liver Disease
Completed	`NCT02528305` - The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis	N/A
Recruiting	`NCT01056133` - Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH)	Phase 2
Completed	`NCT02960204` - Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension	Phase 2
Completed	`NCT04806750` - Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension	Phase 2
Recruiting	`NCT05751720` - Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue	Phase 1/Phase 2

NCT number	NCT03421431
Study type	Interventional
Source	Enanta Pharmaceuticals
Contact
Status	Completed
Phase	Phase 2
Start date	April 25, 2018
Completion date	July 10, 2019

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms